Rapid liquid biopsy for Mohs surgery: rare target cell separation from surgical margin lavage fluid with a high recovery rate and selectivity

Lab on a Chip ◽  
2019 ◽  
Vol 19 (6) ◽  
pp. 974-983
Author(s):  
Wenbo Zhou ◽  
Yaoping Liu ◽  
Menglong Ran ◽  
Xiaofan Zhao ◽  
Hang Li ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Target Cell ◽  
Liquid Biopsy ◽  
Cell Separation ◽  
Surgical Margin ◽  
Residual Tumor ◽  
Lavage Fluid ◽  
High Recovery ◽  
Mohs Surgery ◽  
High Recovery Rate

A liquid biopsy was established for rapid and sensitive examination of residual tumor cells on surgical margin during Mohs surgery.

Fundamentals of integrated ferrohydrodynamic cell separation in circulating tumor cell isolation

Lab on a Chip ◽  
2021 ◽  
Author(s):  
Yang Liu ◽  
Wujun Zhao ◽  
Rui Cheng ◽  
Bryana N. Harris ◽  
Jonathan R. Murrow ◽  
...  
Keyword(s):  
Tumor Cell ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Recovery Rate ◽  
Cell Separation ◽  
Circulating Tumor Cell ◽  
Fundamental Theory ◽  
High Recovery ◽  
High Recovery Rate ◽  
Experimental Validations

We present the fundamental theory and experimental validations of an integrated ferrohydrodynamic cell separation (iFCS) method that can isolate circulating tumor cells with a high recovery rate.

scholarly journals Label-free ferrohydrodynamic cell separation of circulating tumor cells

Lab on a Chip ◽  
2017 ◽  
Vol 17 (18) ◽  
pp. 3097-3111 ◽  
Author(s):  
Wujun Zhao ◽  
Rui Cheng ◽  
Brittany D. Jenkins ◽  
Taotao Zhu ◽  
Nneoma E. Okonkwo ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
High Throughput ◽  
Recovery Rate ◽  
Cell Separation ◽  
Label Free ◽  
High Recovery ◽  
High Recovery Rate

A size-based ferrohydrodynamic cell separation (FCS) device capable of enriching intact circulating tumor cells with high throughput and high recovery rate.

Cell free DNA as an evolving liquid biopsy biomarker for initial diagnosis and therapeutic nursing in Cancer- An evolving aspect in Medical Biotechnology

2020 ◽  
Vol 21 ◽  
Author(s):  
Suman Kumar Ray ◽  
Sukhes Mukherjee
Keyword(s):  
Tumor Cells ◽  
Liquid Biopsy ◽  
Cancer Metastasis ◽  
Nuclear Dna ◽  
Fragment Size ◽  
Body Fluids ◽  
Response To Therapy ◽  
Significant Information ◽  
Cell Free Dna ◽  
Free Dna

: Cell-free DNA (cfDNA) is present in numerous body fluids in addition to initiates generally from blood cells. It is undoubtedly the utmost promising tool among all components of liquid biopsy. Liquid biopsy is a specialized method investigating the nonsolid biological tissue by revealing of circulating cells, cell free DNA etc. that enter body fluids. Since, cancer cells disengage from compact tumors circulate in peripheral blood, evaluating blood of cancer patients holds the opportunities for capture and molecular level analysis of various tumor-derived constituents. Cell free DNA samples can deliver a significant perceptions into oncology, for instance tumor heterogeneity, instantaneous tumor development, response to therapy and treatment, comprising immunotherapy and mechanisms of cancer metastasis. Malignant growth at any phase can outhouse tumor cells in addition to fragments of neoplasticity causing DNA into circulatory system giving noble sign of mutation in the tumor at sampling time. Liquid biopsy distinguishes diverse blood based evolving biomarkers comprising circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) or cfDNA, circulating RNA (cfRNA) and exosomes. Cell free DNA are little DNA fragments found circulating in plasma or serum, just as other fluids present in our body. Cell free DNA involves primarily double stranded nuclear DNA and mitochondrial DNA, present both on a surface level and in the lumen of vesicles. The probable origins of the tumor-inferred portion of cfDNA are apoptosis or tumor necrosis, lysis of CTCs or release of DNA from the tumor cells into circulation. The evolution of innovations, refinement and improvement in therapeutics for determination of cfDNA fragment size and its distribution provide significant information related with pathological conditions of the cell, thus emerging as promising indicator for clinical output in medical biotechnology.

scholarly journals High Clinical Value of Liquid Biopsy to Detect Circulating Tumor Cells and Tumor Exosomes in Pancreatic Ductal Adenocarcinoma Patients Eligible for Up-Front Surgery

Cancers ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 1656 ◽  
Author(s):  
Etienne Buscail ◽  
Catherine Alix-Panabières ◽  
Pascaline Quincy ◽  
Thomas Cauvin ◽  
Alexandre Chauvet ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Liquid Biopsy ◽  
Neoadjuvant Treatment ◽  
Digital Pcr ◽  
Portal Blood ◽  
Ductal Adenocarcinoma ◽  
Clinical Value ◽  
Liquid Biopsies

Purpose: Expediting the diagnosis of pancreatic ductal adenocarcinoma (PDAC) would benefit care management, especially for the start of treatments requiring histological evidence. This study evaluated the combined diagnostic performance of circulating biomarkers obtained by peripheral and portal blood liquid biopsy in patients with resectable PDAC. Experimental design: Liquid biopsies were performed in a prospective translational clinical trial (PANC-CTC #NCT03032913) including 22 patients with resectable PDAC and 28 noncancer controls from February to November 2017. Circulating tumor cells (CTCs) were detected using the CellSearch® method or after RosetteSep® enrichment combined with CRISPR/Cas9-improved KRAS mutant alleles quantification by droplet digital PCR. CD63 bead-coupled Glypican-1 (GPC1)-positive exosomes were quantified by flow cytometry. Results: Liquid biopsies were positive in 7/22 (32%), 13/22 (59%), and 14/22 (64%) patients with CellSearch® or RosetteSep®-based CTC detection or GPC1-positive exosomes, respectively, in peripheral and/or portal blood. Liquid biopsy performance was improved in portal blood only with CellSearch®, reaching 45% of PDAC identification (5/11) versus 10% (2/22) in peripheral blood. Importantly, combining CTC and GPC1-positive-exosome detection displayed 100% of sensitivity and 80% of specificity, with a negative predictive value of 100%. High levels of GPC1+-exosomes and/or CTC presence were significantly correlated with progression-free survival and with overall survival when CTC clusters were found. Conclusion: This study is the first to evaluate combined CTC and exosome detection to diagnose resectable pancreatic cancers. Liquid biopsy combining several biomarkers could provide a rapid, reliable, noninvasive decision-making tool in early, potentially curable pancreatic cancer. Moreover, the prognostic value could select patients eligible for neoadjuvant treatment before surgery. This exploratory study deserves further validation.

scholarly journals Isolation of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Using a Novel Cell Separation Strategy

2011 ◽  
Vol 17 (11) ◽  
pp. 3783-3793 ◽  
Author(s):  
Wen Xu ◽  
Lu Cao ◽  
Lei Chen ◽  
Jing Li ◽  
Xiao-Feng Zhang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Cell Separation ◽  
Separation Strategy

What are the risk factors for residual tumor cells after endoscopic complete resection in gastric epithelial neoplasia?

2014 ◽  
Vol 29 (2) ◽  
pp. 487-492 ◽  
Author(s):  
Gak Won Yun ◽  
Jie-Hyun Kim ◽  
Yong Chan Lee ◽  
Sang Kil Lee ◽  
Sung Kwan Shin ◽  
...  
Keyword(s):  
Risk Factors ◽  
Tumor Cells ◽  
Residual Tumor ◽  
Complete Resection ◽  
Gastric Epithelial Neoplasia
Sign in / Sign up

Export Citation Format

Share Document